Screening Mild and Major Neurocognitive Disorders in Parkinson’s Disease
Table 3
Diagnostic accuracy of screening tests for detecting major neurocognitive disorder due to Parkinson’s disease.
Diagnostic accuracy
MoCA
ACE
MMSE
MDRS
Estimation
Lower 95% CI
Upper 95% CI
Estimation
Lower 95% CI
Upper 95% CI
Estimation
Lower 95% CI
Upper 95% CI
Estimation
Lower 95% CI
Upper 95% CI
Best cut-off score
20.5
80.5
26.5
132.5
Sensitivity
0.921
0.860
0.962
0.869
0.784
0.927
0.692
0.600
0.774
0.566
0.462
0.665
Specificity
0.801
0.738
0.859
0.790
0.737
0.841
0.806
0.752
0.853
0.943
0.905
0.970
Positive predictive value
0.750
0.674
0.816
0.640
0.550
0.714
0.623
0.534
0.707
0.812
0.699
0.896
Negative predictive value
0.953
0.917
0.980
0.921
0.874
0.945
0.850
0.798
0.893
0.835
0.784
0.878
Diagnostic accuracy
0.863
0.823
0.897
0.814
0.764
0.879
0.770
0.724
0.812
0.830
0.785
0.869
Likelihood ratio of a positive test
5.457
4.081
7.297
4.284
3.292
5.575
3.575
2.704
4.725
10.008
5.742
17.442
Likelihood ratio of a negative test
0.095
0.052
0.172
0.162
0.097
0.269
0.382
0.289
0.504
0.460
0.367
0.578
Major neurocognitive disorder because Parkinson’s disease was defined by the Diagnostic and Statistical Manual of Mental Disorders 5th edition criteria. ACE: Addenbrooke’s Cognitive Examination; CI: confidence interval; MDRS: Mattis Dementia Rating Scale; MMSE: Mini Mental State Examination; MoCA: Montreal Cognitive Assessment.
